US 12,251,399 B2
Inducing caspase activity
Caroline Woelfle-Gupta, Midland, MI (US); Andrew Scott, Midland, MI (US); Matthew LeBaron, Midland, MI (US); Daniel Wilson, Midland, MI (US); Susan L. Jordan, Doylestown, PA (US); Robert L. Schmitt, Harleysville, PA (US); and Raja Settivari, Midland, MI (US)
Assigned to Dow Global Technologies LLC, Midland, MI (US)
Appl. No. 17/436,250
Filed by Dow Global Technologies LLC, Midland, MI (US)
PCT Filed Feb. 27, 2020, PCT No. PCT/US2020/020028
§ 371(c)(1), (2) Date Sep. 3, 2021,
PCT Pub. No. WO2020/180581, PCT Pub. Date Sep. 10, 2020.
Claims priority of provisional application 62/813,853, filed on Mar. 5, 2019.
Prior Publication US 2022/0175822 A1, Jun. 9, 2022
Int. Cl. A61K 31/765 (2006.01); A61P 35/00 (2006.01)
CPC A61K 31/765 (2013.01) 6 Claims
 
1. A method of inducing caspase activity, the method comprising contacting a colorectal cancer cell with a treatment compound represented by the following Formula:

OG Complex Work Unit Chemistry
where the treatment compound is a random ethylene oxide/propylene oxide copolymer prepared from a propylene glycol and/or dipropylene glycol initiator reacted with a mixed feed of ethylene oxide and propylene oxide, R1 is selected from hydrogen and a hydroxyl group, R2 is selected from hydrogen and a hydroxyl group, R1 is different than R2, and a sum of x and y is from 4 to 20,000; wherein the treatment compound has a number average molecular weight from 200 to 2,000,000 g/mol.